Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177998 | 0.81 | IDO1 (0.42) | MAOBMAOA | |
| SCHEMBL21178030 | 0.79 | IDO1 (0.49) | MAOBMAOA | |
| SCHEMBL21178000 | 0.78 | IDO1 (0.42) | MAOB | |
| SCHEMBL1060869 | 0.78 | IDO1 (0.42) | MAOBMAOAHTTALDH1A1 | |
| SCHEMBL22801228 | 0.77 | DPP4 (0.40) | — | |
| SCHEMBL21178234 | 0.76 | CYP3A4 (0.49) | MAOBMAOA | |
| SCHEMBL21177999 | 0.76 | TDP1 (0.33) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL28402357 | 0.75 | MAOB (0.40) | MAOBMAOAHTR6ACHEHTT | |
| SCHEMBL22801194 | 0.75 | IDO1 (0.52) | ACHEL3MBTL1 | |
| SCHEMBL2252915 | 0.74 | TSHR (0.41) | MAOAHTTALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427550-B2 | 5-fluorouracil compounds | NUCORION PHARMACEUTICALS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
| WO-2019143860-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | DPYD, DHFR, FAU | MAOB 846/4885MAOA 986/4885HTR6 144/4885 |
| US-11427550-B2 | 5-fluorouracil compounds | DPYD, DHFR, MTHFD1 | MAOB 808/4885MAOA 980/4885HTR6 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.